Expression of Sodium-glucose Co-transporter 2 in Human Heart - Trial NCT05830760
Access comprehensive clinical trial information for NCT05830760 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Strasbourg, France and is currently Not yet recruiting. The study focuses on Aortic Valve Stenosis. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Strasbourg, France
Timeline & Enrollment
N/A
Jun 01, 2023
Oct 01, 2025
Primary Outcome
To study the expression levels of SGLT2 in the myocardium of patients with surgical aortic stenosis,To study the SGLT2 tissue localization in the myocardium of patients with surgical aortic stenosis
Summary
The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2)
 in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group
 A with diastolic heart failure and Group B without heart failure. The expression of SGLT2
 will be measured on small myocardium specimens harvested during aortic valve replacement
 operation. This study should allow us to better understand the effect of glifozines in human
 heart failure.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05830760
Non-Device Trial